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Alemtuzumab, a humanised CD52 monoclonal antibody,
is routinely used as treatment for patients with refractory
chronic lymphocytic leukaemia (CLL). Although alemtu-
zumab has been evaluated in numerous prospective clini-
cal trials, little is known about its safety and efficacy in the
routine clinical practice setting. Given that the haematol-
ogy centers in the Stockholm area has gained substantial
experience on alemtuzumab usage, starting already in the
early 1990s, it would be of interest to compare our results
obtained in routine health care with those from other
reports including multicenter clinical trials.
Records from 1301 patients with CLL from the Stock-
holm-Cancer-Registry (1991-2010) identified 56 patients
treated with alemtuzumab in the relapsed or refractory
setting.
The median age was 69 years, 88% had advanced Rai
stage with a median of 3 prior lines of therapy. One
fourth had bulky lymphadenopathy and 73% were
refractory to purine analogues. The median cumulative
dose of alemtuzumab was 930 mg, being significantly
higher (p=0.0277) for responders (1063 mg) compared
to non-responders (643 mg). The median duration of
therapy for responders was 12.4 weeks (range 7-32
weeks) and in all patients 11.6 weeks (range 1-51
weeks). The overall response rate (ORR) was 43%, with
a response rate of 32.5%, 50% and 87.5% in the refrac-
tory, purine analogue relapsed and non-purine analogue
relapsed group respectively. The differences in response
rate was statistically significant (p=0.0104). A good per-
formance status (PS) was associated with better response
rate (ECOG 0-1 vs. ≥2) (p=0.0227). The median time to
treatment failure (TTTF) was 7.8 months (range
0.4-55.4 months) being significantly longer for respon-
ders, 13.4 months (range 3.9-55.4 months) than for
non-responders, 6.1 months (range 0.9-16.3 months)
(p<0.0001). The median time to next therapy was 12.7
months (range 0.4-55.4 months).
Major infections (defined as ≥ grade III) occurred in 36%
of the patients. Cytomegalovirus reactivation was the most
common opportunistic infection (75%) occurring in
9 patients. Median overall survival was 22.5 months (range
0.4-74.3 months). Responders had a significantly longer
survival than non-responders, 44.2 and 16.3 months
respectively (p=0.0006, log-rank test), although the differ-
ence when using the Landmark method was not signifi-
cant. Predictive factors for longer survival was PS grade
0-1 (p<0.0001) and fewer previous treatment lines (1-3 vs.
≥4) (p=0.0038, log-rank test). Twelve patients were
retreated with alemtuzumab at least once with an ORR of
50% and a TTTF of 7 months (range 0.5-13 months).
In summary, a high cumulative dose/longer duration of
therapy as well as relatively high response rates and long
median survival was observed compared to what has been
reported earlier in similar groups of patients having
received alemtuzumab in trials or in routine health care in
other areas. Optimal patient identification and manage-
ment may result in avoidance of early discontinuation and
possible better treatment outcomes.
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